Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.

Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02181465

Acronym

CC1A&B

Enrollment

Registered

2014-07-04

Start date

1993-10-31

Completion date

1994-05-31

Last updated

2014-07-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models. The hypothesis of this study is that G17DT will elicit specific and high-affinity antibodies that will bind gastrin-17, thus preventing the trophic activity of cancer cells.

Interventions

BIOLOGICALG17DT

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 81 Years

Healthy volunteers

Inclusion criteria

* Histologically verified adenocarcinoma of the colon or rectum * Recurrent/ metastatic disease not amenable to curative surgery and/or radiotherapy * measurable/ evaluable lesions * Life expectancy \> 3 months * Karnofsky index \> 50% or WHO performance rating of 0-2 * Biochemical markers: * renal function \< 25% above upper limit of normal range (creatinine, 140 imol/1 unless malignant involvement proven) * liver function \< 25% above upper limit of normal range (bilirubin \ 25 mcmol/1 unless malignant involvement proven) * Haematological status: * haemoglobin, 11 g/ dl * WBC, 4 X 109/1 * platelets, 100 x 109/l * Written consent

Exclusion criteria

* Other concomitant malignant disease except treated basal cell carcinoma of the skin or cancer of the uterine cervix stage 0-1 * H 2 receptor antagonist or proton pump inhibitor therapy * Previous gastric surgery (including vagotomy) * Active uncontrolled infection * Autoimmune disorders * Anticancer treatment within the last three months unless progression of the disease occurred in the interim * Women of child-bearing age * Patient is a poor medical risk because of non-malignant systemic disease * Previous radiotherapy to all measurable or evaluable lesions.

Design outcomes

Primary

Measure	Time frame
Number of participants with adverse effects	Up to week 16

Secondary

Measure	Time frame
Measure serum anti gastrin-17 antibodies to determine immunological response to medication	Up to week 16

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026